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A B S T R A C T
Background
Between 25% and 35% of infants born to HIV-infected mothers become HIV-1 infected. One
potential route of mother-to-child transmission (MTCT) could be through a breakdown in the
placental barrier (i.e., maternal–fetal microtransfusions).
Methods and Findings
Placental alkaline phosphatase (PLAP) is a 130-kD maternal enzyme that cannot cross the
intact placental barrier. We measured PLAP activity in umbilical vein serum as an indicator of
maternal–fetal microtransfusion, and related this to the risk of HIV-1 MTCT. A case-cohort study
was conducted of 149 women randomly selected from a cohort of HIV-1-infected pregnant
Malawians; these women served as a reference group for 36 cases of in utero MTCT and 43
cases of intrapartum (IP) MTCT. Cord PLAP activity was measured with an immunocatalytic
assay. Infant HIV status was determined by real-time PCR. The association between cord PLAP
activity and HIV-1 MTCT was measured with logistic regression using generalized estimating
equations. Among vaginal deliveries, PLAP was associated with IP MTCT (risk ratio, 2.25 per
log10 ng/ml PLAP; 95% confidence interval, 0.95–5.32) but not in utero MTCT. In a multivariable
model adjusted for HIV-1 RNA load, chorioamnionitis, and self-reported fever, the risk of IP
MTCT almost tripled for every log10 increase in cord PLAP activity (risk ratio, 2.87; 95%
confidence interval, 1.05–7.83).
Conclusion
These results suggest that during vaginal deliveries, placental microtransfusions are a risk
factor for IP HIV-1 MTCT. Future studies are needed to identify factors that increase the risk for
microtransfusions in order to prevent IP HIV-1 MTCT.
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Introduction
By the end of 2004, sub-Saharan Africa was home to 13.3
million HIV-1-infected women, and in many sub-Saharan
countries, the HIV-1 prevalence in antenatal women ex-
ceeded 20% [1]. In the absence of interventions such as
antiretroviral drug prophylaxis, elective cesarean sections,
and replacement feeding, between 25% and 35% of the
children born to HIV-1-positive women themselves become
infected [2]. Of the infant infections, approximately one-half
occur during labor and delivery through an unknown
mechanism [3].
One potential mechanism of HIV-1 mother-to-child trans-
mission (MTCT) is through direct contact of infant mucosa
with HIV-1-infected maternal blood, amniotic fluid, or
cervical/vaginal secretions (the ‘‘all mucosal’’ mechanism)
[4]. Evidence for the importance of this mechanism during
intrapartum (IP) MTCT includes the observations that
elective caesarean sections reduce HIV-1 MTCT [5], and that
higher quantities of HIV-1 secreted into the birth canal are
associated with increased HIV-1 MTCT [6,7]. On the other
hand, both birth canal disinfection and emergency cesarean
sections reduce birth canal exposure to HIV-1, but neither
intervention significantly reduces HIV-1 MTCT [5,8–11].
In addition to the ‘‘all mucosal’’ hypothesis, HIV-1 MTCT
could also occur via a breakdown in the maternal–fetal
barrier followed by placental microtransfusions. Placental
microtransfusions have previously been suggested as a route
of HIV-1 transmission [12–15], and they are considered a
plausible route of hepatitis B, C, and G vertical transmission
[16–18]. Recently, an assay has been developed to quantify
placental microtransfusions based on the detection of
placental alkaline phosphatase (PLAP) activity in umbilical
cord serum [13,15]. PLAP is a 130-kD glycoprotein synthe-
sized from the eighth week of gestation until parturition, and
its large molecular size is believed to preclude its passive
diffusion across the placental barrier. Based on these
characteristics and the observation that infants produce
small amounts of PLAP compared to pregnant women, cord
PLAP can be used as a surrogate marker of placental
microtransfusions [13].
Although the cause of placental microtransfusions is
unknown, they are hypothesized to arise during the first
stage of labor, when uterine contractions intensify and
membranes rupture [3,12,13]. In support of this hypothesis,
cesarean sections performed before the onset of labor result
in significantly less cord PLAP activity than both emergency
cesarean deliveries and spontaneous vertex deliveries [13,15].
To build on these observations and to expand our knowledge
of the biological mechanism of HIV-1 MTCT, we measured
cord PLAP activity in Malawian mother–offspring pairs and




This case-cohort study was derived from the Malaria and
HIV in Pregnancy (MHP) prospective cohort study that was
approved by the College of Medicine Research Committee at
the University of Malawi and the Institutional Review Boards
of the University of Michigan and the University of North
Carolina at Chapel Hill. From December 2000 until March
2004, women in the Antenatal Ward at Queen Elizabeth
Central Hospital in Blantyre, Malawi, were screened for
eligibility to participate in a prospective cohort study
designed to determine the association between malaria and
HIV-1 MTCT. Women were ineligible for the study if they
were in the active phase of labor, were participating in other
research studies, lived outside the Blantyre district, were less
than 15 y of age, were hypertensive, or had altered conscious-
ness. Consenting women received HIV pre- and post-test
counseling, and all HIV-1-infected women and their offspring
received nevirapine according to the HIVNET 012 protocol
[19]. The association between malaria and HIV-1 viral load in
the MHP cohort has been described previously [20].
Case-Cohort Design
We constructed a case cohort study from the parent MHP
prospective cohort. With this study design, a rare disease
assumption is unnecessary and the odds ratio provides a
direct estimate of the risk ratio (RR) [21]. Between December
2000 and February 2003, 2,557 pregnant women were
recruited in the MHP study, of whom 744 (29.1%) were HIV
infected. After identifying all cases of in utero (IU) and IP
MTCT in the parent cohort, we randomly selected 160
women, regardless of their HIV-1 transmission status, from
the 744 HIV-1-positive women to serve as a reference cohort.
Of these mother–offspring pairs, three were excluded
because of multiple gestations, six were excluded because
they delivered at home (therefore cord serum was unavail-
able), and two were excluded because the mother died during
delivery; the remaining 149 HIV-infected women formed the
reference cohort of the case-cohort study (Figure 1). All cases
of IU MTCT were selected from women enrolled in the MHP
study through February 2003, and all cases of IP MTCT were
selected from women enrolled in the MHP study through
June 2003. IP transmission cases selected from February to
June 2003 did not differ from the other IP transmission cases
in terms of age, peripheral HIV-1 RNA load, PLAP activity,
hemoglobin concentration, placental malaria infection, or
mode of delivery (data not shown). HIV-1 MTCT cases were
considered IU transmissions if the infant was positive for
HIV-1 DNA within 48 h of birth, and were considered IP
transmissions (i.e., HIV-1 infection occurring at or around
the time of delivery) if the infant was both negative for HIV-1
Figure 1. Case-Cohort Profile
DOI: 10.1371/journal.pmed.0030010.g001
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DNA within 48 h of birth and positive for HIV-1 DNA 6 wk
after delivery [22].
Laboratory/Pathology Testing
Chorioamnionitis was assessed by a board-certified pathol-
ogist (DM) according to the methods described in [23].
Peripheral malaria infection was assessed on thick blood films
stained with field stain. Placental malaria was diagnosed from
formalin-fixed placental biopsies as described in [24].
Maternal hemoglobin concentration was determined by
HemoCue hemoglobinometer (HemoCue, Ängelholm, Swe-
den), and CD4-positive T cells were quantified by FACScan
(Becton Dickinson, San Jose, California, United States).
HIV-1 Testing
Within the MHP cohort, maternal HIV-1 status was
determined concurrently with both the Determine HIV-1/2
Rapid Test (Abbott Laboratories, Abbott Park, Illinois,
United States) and the SeroCard HIV-1/2 Rapid Test (Trinity
Biotech, Bray, Ireland). HIV-1 RNA was quantified using
Amplicor HIV-1 Monitor v1.5 (Roche Diagnostics, Branch-
burg, New Jersey, United States), with plasma HIV-1 RNA
concentrations less than 400 copies/ml assigned a value of 400
copies/ml. Infants were considered HIV-1 infected based on
the detection of HIV-1 DNA with a real-time PCR assay
against the HIV-1 long terminal repeat [25]. Maternal HIV-1
proviral load was quantified according to the methods
presented in [6].
PLAP Assay
Immediately after delivery the umbilical cord was clamped
and cut. A section of the umbilical cord 3 cm from its point of
insertion into the placenta was washed with saline, the
umbilical vein was located, and cord blood was aspirated with
a large-bore needle. Serum was prepared from the blood and
stored at80 8C. PLAP was isolated from 100 ll of cord serum
using an isoform-specific anti-PLAP antibody (clone B431,
Biomeda, Foster City, California, United States), and its
activity was measured with an immunocatalytic assay accord-
ing to the methods of Hirano et al. [26] with the following
modification: a fluorescent alkaline phosphatase substrate (5
lM fluorescein diphosphate, Molecular Probes, Eugene,
Oregon, United States) was used, and its fluorescence was
measured on a PerkinElmer (Wellesley, Massachusetts, United
States) fluorimeter (excitation k ¼ 490 nm, 10-nm slit width;
emission k¼ 514 nm, 2.5-nm slit width, 515-nm cutoff filter).
Cord PLAP concentration was determined by interpolation
from a standard curve of purified human PLAP (Sigma, St.
Louis, Missouri, United States). The standard curve was linear
from 12 ng/ml to 3,250 ng/ml (R2¼ 0.992), with PLAP activity
less than 12 ng/ml assigned a value of 12 ng/ml.
Statistical Methods
IU and IP MTCT cases were analyzed as independent
outcomes. We used generalized estimating equations with a
logit link, binomial distribution, and an independent corre-
lation structure to conduct bivariable and multivariable
assessments of the relationship between maternal features
and MTCT, while accounting for the lack of independence of
the 23 MTCT cases included in the sub-cohort. To reflect the
monotonically increasing risk of IP transmission as PLAP
increased, log10 cord PLAP was coded as a continuous
variable. In the multivariable models, prior to the outcome
analysis, we assessed heterogeneity of the odds ratio by testing
for interaction terms at a ¼ 0.1. Subsequently, confounding
was assessed by the backward elimination method [21] based
on the change in the point estimate; variables that changed
the estimate (RR) more than 10% were retained in the final
model, with the exception of maternal HIV-1 viral load,
which was included a priori. Variables assessed for inter-
action and potential confounding of HIV-1 MTCT prior to
the outcome analysis include the following: HIV-1 RNA load,
HIV-1 DNA load, CD4 T cell count , 200 cells/ll,
chorioamnionitis (present or absent), episiotomy, self-re-
ported fever in the week prior to enrollment, gestational age,
placental malaria (any Plasmodium falciparum–infected eryth-
rocytes on placental histology), and rupture of membranes
more than 4 h prior to delivery. Owing to the correlation
between HIV-1 RNA load, HIV-1 DNA load, and CD4 T cell
count, the multivariable model of MTCT contained only one
of these measures of HIV burden. Before the analysis of the
association between maternal features and log10 cord PLAP,
we eliminated duplicate values by removing the 23 cases
included in the sub-cohort. The relationships between PLAP
and dichotomous maternal factors were assessed with a two-
tailed unpaired t-test (a ¼ 0.05), and with continuous
maternal factors the relationship was assessed with Pearson’s
correlation coefficient (a ¼ 0.05). Statistical analysis was
performed with STATA v8.2 (StataCorp, College Station,
Texas, United States).
Results
We designed a case-cohort study to independently compare
36 IU and 43 IP MTCT cases to a sub-cohort of 149 HIV-
positive mothers. The IU and IP MTCT cases were similar to
the sub-cohort in terms of maternal age, infant birth weight,
maternal hemoglobin concentration, gestational age, and
gravidity (Table 1). The groups did not differ in the
proportion of chorioamnionitis infections, nor in the
proportion of peripheral or placental malaria infections. Of
205 deliveries, 149 (73%) were spontaneous vertex deliveries,
40 (20%) were emergency cesarean sections, seven (3%) were
instrumental vaginal deliveries, five (2%) were elective
cesarean sections, and four (2%) were breech deliveries; the
mode of delivery did not differ significantly between study
groups.
As expected, HIV-1 RNA concentration was associated with
MTCT. The median HIV-1 RNA load of the mother in IU
MTCT cases was twice the median HIV-1 RNA load of the
sub-cohort (67,646 copies/ml versus 35,241 copies/ml), and in
a univariable regression, the risk of IU transmission increased
65% for every log10 increase in HIV RNA load (RR, 1.65; 95%
confidence interval [CI], 1.06–2.58). Similarly, the median
HIV-1 RNA load of the mother in IP MTCT cases was
approximately twice the median RNA load of the sub-cohort
(76,544 copies/ml versus 35,241 copies/ml), and the risk of IP
MTCT increased 76% per log10 increase in HIV-1 RNA (RR,
1.76; 95% CI, 1.10–2.81). No statistically significant associa-
tion between MTCT and either HIV DNA level or CD4 count
was observed.
To validate PLAP as a marker for placental microtransfu-
sions, we determined whether cord PLAP was associated with
mode of delivery and gestational age. Cord serum was
available for 177/205 (87%) of the enrolled mother–offspring
PLoS Medicine | www.plosmedicine.org January 2006 | Volume 3 | Issue 1 | e100072
Placental Microtransfusions and HIV MTCT
pairs. Mean cord PLAP activity was lower in elective cesarean
deliveries than in spontaneous vertex deliveries (1.43 log10 ng/
ml versus 1.82 log10 ng/ml, t¼2.09, p¼ 0.039), and it was also
lower in elective cesarean deliveries than in emergency
cesarean sections (1.43 log10 ng/ml versus 1.81 log10 ng/ml, t
¼ 1.78, p ¼ 0.083). In addition, cord PLAP activity was
directly correlated with gestational age (n ¼ 174, correlation
coefficient¼ 0.18, p¼0.017), and therefore preterm deliveries
(,37 wk) had lower cord PLAP than term deliveries (37–40
wk) (1.68 log10 ng/ml versus 1.84 log10 ng/ml, t ¼ 1.91, p ¼
0.058). In contrast, log10 cord PLAP was not associated with
the following maternal variables: rupture of membranes more
than 4 h prior to delivery (n¼163, t¼0.74, p¼0.46), placental
malaria (n ¼ 167, t ¼0.12, p ¼ 0.90), chorioamnionitis (n ¼
162, t¼ 0.85, p¼ 0.40), duration of labor (n¼ 177, correlation
coefficient ¼0.0001, p ¼ 0.99), log10 HIV-1 RNA load (n ¼
170, correlation coefficient ¼ 0.012, p ¼ 0.88), or CD4 T cell
count (n ¼ 171, correlation coefficient ¼ 0.12, p ¼ 0.105).
Therefore, the only maternal factors associated with cord
PLAP were mode of delivery and gestational age.
The association between IP HIV MTCT and cord PLAP
concentration was also measured. This association varied by
the mode of delivery (p ¼ 0.058), so prior to the analysis, the
data were stratified by mode of delivery. In a univariable
model of 119 spontaneous vaginal deliveries, elevated cord
PLAP activity increased the risk of IP MTCT (RR, 2.25 per
log10 ng/ml PLAP; 95% CI, 0.95–5.32); a bivariable model that
included log10 HIV RNA load yielded a similar association
(RR, 2.01; 95% CI, 0.84–4.79; n ¼ 115). After adjusting the
model for self-reported fever and chorioamnionitis, cord
PLAP activity was significantly associated with IP MTCT (RR,
2.82 per log10 increase in cord PLAP; 95% CI, 1.04–7.67; n ¼
103; Table 2). The risk of IP MTCT associated with cord PLAP
increased slightly if maternal CD4 T cell count or HIV-1 DNA
load was substituted for HIV-1 RNA load, although the
precision of the estimates varied (Table 2). For emergency
cesarean section deliveries (n¼ 32), although the trend of the
data suggests an inverse relationship, log10 PLAP was not
associated with IP MTCT (RR, 0.32; 95% CI, 0.04–2.68). Small
sample sizes precluded the analysis of an association between
cord PLAP and HIV MTCT during instrumental vaginal,
elective cesarean section, and breech deliveries. Thus, among
vaginal deliveries, placental microtransfusions appear to be a
risk factor for IP HIV-1 transmission.
Finally, we analyzed the risk of IU MTCT from placental
microtransfusions. In a univariable analysis of 159 mother–
offspring pairs, log10 cord PLAP activity was not significantly
associated with IU MTCT (RR, 0.54; 95% CI, 0.26–1.13).
Inclusion of HIV-1 RNA load, preterm delivery, syphilis
infection, chorioamnionitis, and placental malaria infection
as covariates in the model did not change the magnitude of
the relationship between cord PLAP and IU MTCT, which
remained nonsignificant (data not shown). Thus, these data
provide no evidence of an association between placental
microtransfusions and IU HIV transmission.
Discussion
In this case-cohort study of Malawian mother–offspring
pairs, we tested the hypothesis that placental microtransfu-
sions, as measured by cord PLAP activity, are an additional
mechanism of HIV-1 MTCT. In support of this hypothesis,
our data show that for every log10 increase in cord PLAP, the
risk of IP transmission during vaginal deliveries almost
tripled. Importantly, this increased risk of transmission
remained after adjustment for HIV-1 RNA load, which is
Table 1. Enrollment Characteristics
Characteristic Subcategory Sub-Cohort (n ¼ 149) IU MTCT (n ¼ 36) IP MTCT (n ¼ 43)
Age, median (25th–75th percentile) 24 (20–28) 23 (21–26) 24 (21–29)
Birthweight , 2.5 kg 37/149 (25) 11/36 (31) 12/43 (28)
CD4 T cells (cells/ll) ,200 37/142 (26) 7/34 (21) 16/43 (37)
200–499 73/142 (51) 17/34 (50) 17/43 (40)
500 32/142 (23) 10/34 (29) 10/43 (23)
Chorioamnionitis 34/125 (27) 13/36 (36) 15/39 (38)
Preterm deliveries (,37 wk) 32/144 (22) 11/35 (31) 10/42 (24)
Gravidity 1 41/149 (28) 14/36 (39) 11/43 (26)
2–4 91/149 (61) 20/36 (56) 25/43 (57)
.4 17/149 (11) 2/36 (6) 7/43 (17)
Hemoglobin (g/dl), median (25th–75th percentile) 10.9 (9.70–12.0) 10.8 (10.1–12.7) 10.6 (9.3–11.5)
HIV DNA load (log2 copies), median (25th–75th percentile) 13.3 (10.8–15) 13.9 (12.6–16.4)
a 13.8 (12.7–15.1)
HIV-1 RNA load (copies/ml), median (25th–75th percentile) 35,241 (10,711–126,205) 67,646 (13,975–177,458)b 76,544 (25,791–218,950)c
Mode of delivery Elective cesarean section 4/149 (3) 2/36 (6) 0/43 (0)
Emergency cesarean section 32/149 (21) 5/36 (14) 6/43 (14)
Vaginal (instrumental) 5/149 (3) 0/36 (0) 2/43 (5)
Vaginal (breech) 3/149 (2) 1/36 (2) 1/43 (2)
Vaginal (spontaneous vertex) 105/149 (70) 28/36 (78) 34/43 (79)
Peripheral malaria 14/149 (9) 2/36 (6) 4/43 (9)
Placental malaria None 75/134 (56) 18/32 (56) 23/38 (61)
Current 24/134 (18) 5/32 (16) 7/38 (18)
Past 35/134 (26) 9/32 (28) 8/38 (21)
Data are n/total (%) unless listed otherwise.
aRR ¼ 1.11 (95% CI: 0.99–1.23) per log2 increase in HIV DNA (copies).
bRR ¼ 1.65 (95% CI: 1.06–2.58) per log10 increase in HIV RNA (copies/ml).
cRR ¼ 1.76 (95% CI: 1.10–2.81) per log10 increase in HIV RNA (copies/ml).
DOI: 10.1371/journal.pmed.0030010.t001
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the most consistently reported risk factor for HIV-1 vertical
transmission (reviewed in [27]).
In contrast to IP transmission during vaginal deliveries,
placental microtransfusions were not significantly associated
with IU HIV-1 transmission. The lack of association between
IU MTCT and placental microtransfusions may result from
the short half-life of PLAP in infants (;5 d) [13]; therefore,
because PLAP activity is measured at the time of delivery,
PLAP that passed into fetal circulation in the weeks prior to
parturition might not persist until the time of delivery, and
an association with IU MTCT, if it existed, would be missed.
Although a possible inverse relationship between PLAP and
IP MTCT during emergency cesarean sections was observed,
the small number of IP transmission cases in this stratum (n¼
6) and the wide confidence intervals of this association (95%
CI, 0.04–2.68) preclude a reliable conclusion.
The cord PLAP measurements in this study are consistent
with previous studies in two ways. First, gestational age was
directly correlated with cord PLAP activity, which is a result
of the increase in maternal PLAP production over the course
of a pregnancy [28]. Second, compared to both vaginal and
emergency cesarean section deliveries, elective cesarean
sections produced the smallest amount of microtransfusion
[13,15]. Because only elective cesarean sections eliminate
labor, the relationship between mode of delivery and cord
PLAP activity has been attributed to a disruption of the
placental barrier by labor and contractions. In support of this
theory, Kaneda and colleagues reported a direct correlation
between cord PLAP activity and prolonged labor (5 h) [13].
We did not observe a similar correlation among women who
entered labor, and this could be explained in two ways:
recording the duration of labor was not the primary concern
of the study, so it is possible that our measurements were
imprecise, or other features of labor such as the frequency
and/or intensity of contractions may more strongly influence
maternal–fetal transfusions.
Besides labor, placental infection or inflammation could
also compromise the maternal–fetal barrier. A common
source of placental pathology in sub-Saharan Africa is
malaria, and although 17% of the women in this study had
active placental malaria at the time of delivery, we detected
no association between cord PLAP and placental malaria. A
second potential source of placental inflammation is cho-
rioamnionitis, which has been associated with HIV-1 MTCT
[29]. Although 30% of the women in this study had
chorioamnionitis, it also was not associated with cord PLAP.
Based on these observations, there is no evidence from this
study that placental malaria or chorioamnionitis increases
placental microtransfusions.
The most probable confounding factor in this study is
gestational age, which has been associated with both HIV
transmission and maternal PLAP concentration. However,
although the gestational age differed between the case-cohort
groups, inclusion of gestational age in our IP transmission
model did not change the risk estimate.
Two potential sources of uncertainty in our RR estimate
are the use of PLAP as a marker of placental micro-
transfusions and the misclassification of HIV-1 transmission.
Any measurement error in the PLAP assay (exposure) is likely
to be nondifferential among the cases and the sub-cohort.
Owing to the timing of infant blood collection (48 h and 6 wk
after delivery), it is also possible that some of the HIV-1
transmission classified as IP was actually acquired late IU or
during early breastfeeding [3]. This misclassification should
be independent of PLAP activity, and therefore our RR
estimate is most likely biased towards the null [21].
In this study investigating the role of maternal–fetal micro-
transfusions in HIV-1 MTCT, our data suggest that, independ-
ent of maternal HIV-1 viral load, placental microtransfusions
during spontaneous vaginal deliveries increase the risk of IP
HIV-1 MTCT. Future studies on the etiology of placental
microtransfusions should provide greater insight into the
mechanism of HIV-1 MTCT and suggest new strategies to
prevent IP HIV-1 transmission in the developing world.
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Patient Summary
Background. Without intervention, between 25% and 35% of the
children born to HIV-positive mothers will themselves be infected. In
about 50% of the cases, transmission from mother to child occurs during
labor and delivery. Scientists don’t yet understand how exactly this
transmission happens. Even so, they have found that some treatments
can prevent most of the mother-to-child transmission of HIV. The
problem is that for many of the HIV-positive pregnant women in
developing countries, these treatments are not available or not
acceptable.
Why Was This Study Done? The hope is that better understanding of
mother-to-child transmission will lead to more effective, more available,
and more acceptable treatments. One possible way children are infected
is through placental microtransfusions, which are exchanges of small
amounts of blood between the mother and the baby. Some degree of
placental microtransfusion occurs in most pregnancies once labor starts,
because the contractions cause small areas of rupture in the placenta,
but the overall amount of blood exchange is likely to differ from delivery
to delivery. Until recently, it was not possible to measure the extent of
these microtransfusions for a particular delivery, but now scientists have
developed an assay in umbilical cord blood that can do this. In this study,
the researchers made use of this new assay to ask whether there is a link
between the extent of placental microtransfusion and the likelihood of
HIV transmission.
What Did the Researchers Do and Find? They studied a group of
mothers and children in Malawi. All of the mothers were HIV-positive,
and some of them transmitted the virus to their children. This
transmission occurred either during the pregnancy or around delivery,
and the researchers knew the timing for each case. They also knew how
the children were born: approximately three-quarters by vaginal delivery
and one-fifth by emergency caesarean section. They determined the
level of placental microtransfusion from the umbilical cord blood and
then looked for correlations between HIV transmission and level of
microtransfusion. They found no correlation for the cases where HIV was
transmitted during pregnancy. For cases of transmission around delivery,
however, higher levels of microtransfusion were associated with a higher
risk of HIV transmission for vaginal deliveries.
What Does This Mean? This suggests that better understanding of what
causes microtransfusions might help researchers devise new strategies
to prevent transmission. However, this will take some time. Because
effective ways to prevent transmission already exist, the immediate goal
must be to make them available to women in developing countries
where transmission still occurs at high frequencies.
Where Can I Find More Information Online? The following Web sites
provide information on mother-to-child transmission of HIV.
World Health Organization pages:
http://www.who.int/reproductive-health/rtis/MTCT/
Joint United Nations Programme on HIV/AIDS pages:
http://www.unaids.org/Unaids/EN/Inþfocus/Topicþareas/
Mother-to-childþtransmission.asp
Unversity of California at San Francisco HIV inSite pages:
http://hivinsite.ucsf.edu/InSite?page¼kbr-07–02–03
Centers for Disease Control and Prevention page:
http://www.cdc.gov/nchstp/od/gap/pmtct/
Los Alamos HIV database:
http://hiv-web.lanl.gov/content/index
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